Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...

With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...

FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...

The real drug development delay? Bad communication.

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA ...